PSC Support was set up over twenty years ago. Supporting and funding research has always been an important part of our work, thanks to your generous donations. We are proud of our grant research programme, which has clearly defined and transparent mechanisms in place, and a robust peer-review process to ensure your donations fund only the highest quality, most worthwhile PSC research. However, we must do more to accelerate this progress. By 2030, we will fund and support more PSC research than ever before, offering over £1 million in grants to researchers as part of our commitment to help find effective treatments for everyone with PSC by 2030.
Studies funded by PSC Support:
Continuing to develop a blood test to detect early bile duct cancer and to predict who is most at risk in people with PSC.
Continuing to develop a blood test to diagnose PSC. His previous research, funded by PSC Support, found ten promising antibody markers which he will now test on a larger scale to find one that is unique to PSC.
Investigating how the cells in people with PSC can develop into bile duct cancer (cholangiocarcinoma).
Investigating the potential of a new treatment (faecal microbiota transplantation) to slow the progression of PSC and improve the quality of life for patients.
PSC-600: discovering new biomarkers for PSC using data from the UK-PSC registry.
Investigating non-invasive biomarkers in blood to predict PSC prognosis and early cholangiocarcinoma (CCA) development.
Creating a personalised psychological intervention for primary sclerosing cholangitis: understanding mental health and wellbeing among people with PSC.
The VAPoR Study: Validating the Prognostic Utility of Vascular Adhesion Protein 1 in PSC.
Identifying the true genes underlying each of the twenty-three known loci associated with risk of developing PSC.
Investigating the effect of male cholestasis (i.e. men with PSC) on the epigenome of sperm and the impact on the health of children of men with cholestasis.
Developing an unbiased screen for novel clinical and molecular biomarkers of the progression of primary sclerosing cholangitis to biliary tract cancer
Investigating the role of non-canonical Wnt signalling in the establishment of fibrosis during PSC